Aduro Biotech Inc.'s research and licensing deal with Eli Lilly and Co. not only provides $12 million up front and potential milestone-related money in the amount of $620 million per product – for an unlimited number of them – but also includes a "nice modularity," as Chief Scientific Officer Andrea van Elsas put it, in the form of an option to co-fund development.